HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy and safety of desmopressin acetate applied for nocturia in benign prostatic hyperplasia patients: A systematic review and meta-analysis.

AbstractBACKGROUND:
Desmopressin acetate was recommended for nocturia in benign prostatic hyperplasia (BPH) patients recently, but its effect and safety is still controversial. We aimed to establish a systematic review and meta-analysis to confirm its effect on symptom relief and adverse effects.
METHODS:
A systematic search was performed in PubMed, Cochrane Library, EMBASE, Medline, Web of Science and Science Direct databases from January 2000 to October 2021 for controlled trials of BPH patients comparing oral desmopressin with control groups. The mean difference (MD) and odds ratio (OR) were meta-analyzed.
RESULTS:
Four articles with 500 patients were included. Significantly greater benefit was detected for the desmopressin group in the improvement of nocturia (P = .004), international prostate symptom score - storage (IPSS-S) (P = .03), and quality of life (QoL) (P = .04) scores. Patients treated with desmopressin were at higher risk than the control group for short-term adverse events (P < .001), including nausea (4.71%, P = .04), headache (20%, P < .00001), dizziness (5.88%, P = .02) and hyponatremia (4.71%, P = .04), but the long-term incidence might decrease.
CONCLUSION:
Desmopressin acetate can reduce nocturia frequency and improve the IPSS-S and QoL score in BPH patients. Some adverse reactions of desmopressin, such as hyponatremia, headache, dizziness and nausea, may be mild and short-term. No significant difference of desmopressin was found in improving the overall IPSS score and maximum urine flow.
AuthorsQihua Wang, Rami Alshayyah, Bo Yang
JournalLower urinary tract symptoms (Low Urin Tract Symptoms) Vol. 14 Issue 3 Pg. 155-162 (May 2022) ISSN: 1757-5672 [Electronic] Australia
PMID35034423 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
Copyright© 2022 John Wiley & Sons Australia, Ltd.
Chemical References
  • Deamino Arginine Vasopressin
Topics
  • Deamino Arginine Vasopressin (adverse effects)
  • Dizziness (complications)
  • Headache (complications)
  • Humans
  • Hyponatremia (complications)
  • Male
  • Nausea (complications)
  • Nocturia (drug therapy, etiology)
  • Prostatic Hyperplasia (complications, drug therapy)
  • Quality of Life
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: